Bharat Biotech’s Chairman and MD Dr Krishna Ella, on the launch of the ‘iNCOVACC’ vaccine, said that the vaccine is easy to deliver and doesn’t need any syringe or needle. As the country marked its 74th Republic Day, Union Health Minister Dr Mansukh Mandaviya and Union Science and Technology Minister Jitendra Singh launched Bharat Biotech’s first India-made nasal Covid-19 vaccine, iNCOVACC.
“It’s easy to deliver and doesn’t need any syringe or needle and most important it produces three immune responses, IgG, IgA, & T cell response. No other vaccine in the world can produce three responses compared to the injectable, which produced mostly IgG or T cells response,” said Dr Krishna Ella, Chairman & MD, Bharat Biotech while talking to ANI.
It is developed by Bharat Biotech International Limited (BBIL) in collaboration with Biotechnology Industry Research Assistance (BIRAC), a PSU under the Dept of Biotechnology, Ministry of Science and Technology.
Expressing his elation at the event, Dr Mandaviya said, “Over 65 per cent of vaccines supplied in the world are from India. Congratulating the BBIL team and the dept of Biotech for bringing about the world’s first nasal vaccine, he stated that “being the world’s first intra-nasal COVID19 vaccine, this marks a glorious tribute to the call for Atmanirbhar Bharat”.
The Union Health Minister added that India’s vaccine manufacturing and innovation capability is appreciated all over the world as it has made a mark in producing quality and affordable medicines. He also highlighted that BBIL in collaboration with ICMR introduced COVAXIN in India within a month of the launch of first COVID vaccine in the world.
Congratulating BBIL for innovating another vaccine in collaboration with BIRAC, Dr Jitendra Singh said that “India has taken a lead in developing vaccines and medicines for diseases common in the developing world”.
He credited Prime Minister Narendra Modi’s personal intervention and regular monitoring for inspiring and enabling the launching of “Mission Covid Suraksha” which has not only strengthened AatmaNirbhar Bharat but also bolstered India’s status as a worldwide vaccine development and manufacturing centre, thus showcasing the strength of India’s Science and Technology capabilities.
“Next step would be to develop vaccines for non-communicable diseases”, he added.
He also stated that ZyCoV-D, the world’s first and India’s indigenously developed DNA-based vaccine for Covid-19 to be administered in humans including children and adults 12 years and above, was also developed in partnership with the Department of Biotechnology in the Ministry of Science and Technology under ‘Mission Covid Suraksha’ through BIRAC.
iNCOVACC is a cost-effective covid vaccine which does not require syringes, needles, alcohol wipes, bandages, etc, saving costs related to procurement, distribution, storage, and biomedical waste disposal, that is routinely required for injectable vaccines.
It utilizes a vector-based platform, which can be easily updated with emerging variants leading to large-scale production, within a few months. These rapid response timelines combined with the ability of cost-effective and easy intranasal delivery, make it an ideal vaccine to address future infectious diseases, stated an official release.
A rollout of iNCOVACC is expected to begin in private hospitals that have placed advance orders. An initial manufacturing capacity of several million doses per annum has been established, this can be scaled up to a billion doses as required. iNCOVACC is priced at INR 325/dose for large volume procurement by State Governments and Govt of India, as per an official release.
Dr Rajesh Gokhale, Secretary, Dept of Biotechnology, Shri Rajesh Kumar Pathak, Secretary, of Technology Development Board and other senior officials of the Ministry were present on occasion. Dr Krishna Ella, Co-Founder and Executive Chairman, Bharat Biotech and Smt. Suchitra Ella, Co-Founder and MD, of Bharat Biotech were also present.
(This news report is published from a syndicated feed. Except for the headline, the content has not been written or edited by OpIndia staff)
